

SWISS BIOTECH SUCCESS STORY

Plan-les-Ouates



SELEXIS®

Geneva-based, a scientific pioneer and global leader in mammalian cell line generation

The Selexis SUREtechnology Platform is the most comprehensive set of cell line development and protein expression technologies available and has been designed to address inherent variabilities in a way that consistently delivers highest protein production levels

The platform is the result of 15 years of scientific discoveries and effective large-scale implementation of these innovations. To date, the company has established more than 100 commercial license agreements

Selexis has been granted more than 150 patents in genetic elements, procedures/transfection, cell line engineering, and devices that are related to cell line development and protein expression



THE FOUNDING TEAM



Igor Fisch
Co-founder




Nicolas Mermod
Co-founder




KNOWLEDGE

Scientific pioneer in mammalian cell line generation. The SUREtechnology Platform helps biotechnology and pharmaceutical companies realize the potential of novel protein therapeutics



INDICATIONS

More than 1,000 clonal research cell banks have been generated with the Selexis SUREtechnology Platform in the areas of cancer, autoimmune/inflammatory diseases, blood disorders, metabolic disorders and dermatology/eye disorders



BUSINESS DEVELOPMENT

Selexis works with more than 100 leading companies worldwide to span the full spectrum of life sciences, from academic research to biotechnology development and big pharma manufacturing

SUCCESS CATEGORIES

- ★ New technology
- ★ Product approval and sustainable revenues
- ★ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland